An 11-year review of dermatomyositis in asian patients

Annals of the Academy of Medicine Singapore

Volumn 39, Issue 11, 2010, Pages 843-847

  Liu, Wen Chun ^a   Ho, Madeline ^a   Koh, Woon Puay ^b   Tan, Audrey W H ^a   Ng, Patricia P L ^a   Chua, Sze Hon ^a   Tan, Suat Hoon ^a   Tang, Mark B Y ^a  

^a NATIONAL SKIN CENTRE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Malignancy; Myositis; Nasopharyngeal carcinoma; Photosensitivity

Indexed keywords

ANTINUCLEAR ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; JO 1 ANTIBODY; RO ANTIBODY;

ADOLESCENT; AGE; AGED; ARTICLE; ASIAN; BREAST CARCINOMA; CANCER RISK; CANCER SCREENING; CHILD; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUSCLE WEAKNESS; NASOPHARYNX CARCINOMA; OVARY CARCINOMA; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX DIFFERENCE; UTERUS CARCINOMA;

EID: 78650312250     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Dourmishev LA, Dourmishev AL, Shwartz RA. Dermatomyositis: cutaneous manifestations of its variants. Int J Dermatol 2002;41:625-630.
2. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic infl ammatory myopathies. J Am Acad Dermatol 2006;54:597-613.
3. Sparsa A, Liozon E, Herrmann F, Ly K, Lebrun V, Soria P, et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 2002;138:885-890.
4. Basset-Seguin N, Roujeau JC, Gherardi R, Guillaume JC, Revuz J, Touraine R. Prognostic factors and predictive signs of malignancy in adult dermatomyositis: a study of 32 cases. Arch Dermatol 1990;126:633-637.
5. Leow YH, Goh CL. Malignancy in adult dermatomyositis. Int J Dermatol 1997;36:904-907.
6. Ang P, Sugeng, MW, Chua SH. Classical and amyopathic dermatomyositis seen at the National Skin Centre of Singapore: a 3-year retrospective review of their clinical characteristics and association with malignancy. Ann Acad Med Singapore 2000;29:219-223.
7. McCollough M, Cockerell CJ. Vesiculo-Bullous Dermatomyositis. Am J Dermatopath 1998;20;170-174.
8. Fardet L, Dupuy A, Gain M, Kettaneh A, Cherin P, Bachelez H, et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009;88:91-97.
9. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for dermatomyositis: American Academy of Dermatology. J Am Acad Dermatol 1996;34:824-829.
10. Madan V, Chinoy H, Griffi ths CE, Cooper RG. Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol 2009;34:451-455.
11. Madan V, Chinoy H, Griffi ths CE, Sooper RG. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin Exp Dermatol 2009;34:561-565.
12. Chow WH, Gridley G, Mellemkjaer L, McLaughin JK, Olsen JH, Fraumeni JF Jr. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995;6:9-13.
13. Population trends 2009. Available at: http://www.singstat.gov.sg/pubn/ demo.html#popntrend Accessed 9 March 2010.
14. Bernatsky S, Joseph L, Pineau CA, Belisle P, Boivin JF, Baneriee D, et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis 2009;68:1192-1196.
15. Vargas-Leguás H, Selva-O'Callaghan A, Campins-Martí M, Hermosilla Perez E, Grau-Junyent JM, Martinez Gomez X, et al. Polymyositis-dermatomyositis: incidence in Spain (1997-2004). Med Clin (Barc) 2007;129:721-724.
16. Callen JP. The value of malignancy evaluation in patients with dermatomyositis. J Am Acad Dermatol 1982;6:253-259.
17. Goh CL, Rajan VS. Dermatomyositis in a skin clinic. Ann Acad Med Singapore 1983;12:6-12.
18. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specifi c cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100.
19. Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001;144:825-831.
20. Zhang W, Jiang SP, Huang L. Dermatomyositis and malignancy: a retrospective study of 115 cases. Eur Rev Med Pharmacol Sci 2009;13:77-80.
21. Singapore Cancer Registry Report. Interim Report. Trends in Cancer Incidence in Singapore 2003-2007. National Registry of Diseases Offi ce (NRDO). Available at: http://www.nrdo.gov.sg/uploadedFiles/NRDO/Publications/Cancer%20Trend%20Report%2003-07%20for%20web%20v2.pdf Accessed 29 September 2009.
22. Fardet L, Rybojad M, Gain M, Kettaneh A, Cherin P, Bachelez H, et al. Incidence, risk factors, and severity of herpesvirus infections in a cohort of 121 patients with primary dermatomyositis and dermatomyositis associated with a malignant neoplasm. Arch Dermatol 2009;145:889-893.
23. Hashimoto A, Okuyama R, Watanabe H, Tagami H, Aiba S. Cyto-megalovirus infection complicating immunosuppressive therapy for dermatomyositis. Acta Derm Venereol 2006;86:535-537.
24. Wong KO. Dermatomyositis: a clinical investigation of 23 cases in Hong Kong. Br J Dermatol 1969;81:544-547.
25. Nishigori K, Yamamoto T, Yokozeki H. Vesiculo-bullous dermatomyositis: report of three cases. Dermatol Online J 2009;15:6.
26. Zangrilli A, Papoutsaki M, Bianchi L, Teoli M, Chimenti S. Bullous dermatomyositis: a marker of poor prognosis and aggressive internal malignancy? Acta Derm Venereol 2008;88:393-394.
27. O TM, Yu G, Hu K, Li JC. Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States. Otolaryngol Head Neck Surg 2007;136:992-997.